KPV and Gut Inflammation: What the Colitis Studies Found

LynxLab · 24 October 2026 · 7 min read

The research behind KPV in the gut: the alpha-MSH tail, the PepT1 transporter in inflamed colon, the 2008 colitis studies and the nanoparticle work since.

Photo: Gustavo Fring, Pexels

Of all the places a three-amino-acid peptide might act, the inflamed colon is the one where the research on KPV is deepest. The reason is a transporter protein called PepT1, which is normally confined to the small intestine but shows up in the large bowel during inflammatory bowel disease.

This post walks through that research as it was published: what kpv is, why PepT1 matters, what the two 2008 colitis studies measured in mice, and how later groups tried to deliver the peptide to the colon with nanoparticles and hydrogels. It ends with what has not been done, which is any trial in a human being.

KPV is the last three amino acids of alpha-MSH

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-residue hormone cut from the larger pro-opiomelanocortin protein. Its sequence is SYSMEHFRWGKPV, and the final three letters, lysine-proline-valine, are KPV (Cutuli et al., Journal of Leukocyte Biology, 2000).

Alpha-MSH itself has long been studied as an anti-inflammatory signal. The problem for drug developers is that it also drives pigmentation through melanocortin receptors. A 2008 review in Endocrine Reviews from Thomas Luger's dermatology group in Münster set out the case for KPV as the alternative: the C-terminal tripeptide kept the anti-inflammatory effect in their models but had no pigmentary action (Brzoska et al., Endocrine Reviews, 2008).

That separation is the whole premise of kpv peptide research. If the useful part of alpha-MSH can be isolated in three residues, the tanning problem disappears, and a tripeptide is cheap to make.

PepT1: the transporter that appears in an inflamed colon

PepT1 is an intestinal transporter that pulls di- and tripeptides from the gut lumen into epithelial cells. In a healthy gut its expression follows a strict gradient: highest in the upper small intestine, absent in the colon.

Didier Merlin's group at Emory University reported in 2001 that this changes in disease. In colonic biopsies, PepT1 was present in chronic ulcerative colitis (6 patients) and Crohn's disease (4 patients), but not in normal colon (4 patients) or in microscopic colitis (4 patients) (Merlin et al., Gastroenterology, 2001).

That paper was about a bad consequence: PepT1 in the colon lets bacterial peptides into epithelial cells and ramps up immune signalling. But it also set up a question. If an inflamed colon suddenly has a tripeptide transporter, could a tripeptide use it as a doorway?

The Emory study: KPV rides PepT1 into the cell

Seven years later the same group answered it. Guillaume Dalmasso and colleagues tested KPV in two human intestinal epithelial lines (Caco2-BBE and HT29-Cl.19A) and in Jurkat T cells, each stimulated with pro-inflammatory cytokines (Dalmasso et al., Gastroenterology, 2008).

Nanomolar concentrations of KPV inhibited activation of NF-kappaB and the MAP kinase pathway, measured with a luciferase reporter, Western blot and PCR, and reduced pro-inflammatory cytokine secretion. Uptake experiments with radiolabelled KPV and with cold KPV competing against a known PepT1 substrate showed the peptide entering cells through PepT1 in both the epithelial and the immune cells.

The animal part used two standard colitis models in mice, dextran sulphate sodium (DSS) and TNBS. KPV was added to the drinking water. Oral KPV reduced the incidence of colitis in both models, assessed by histology and by pro-inflammatory cytokine mRNA.

The authors' conclusion was measured: KPV "is transported into cells by PepT1 and might be a new therapeutic agent for IBD". Anyone searching for kpv uk research material should note the word "might", and the species.

The Münster study: two models and a receptor knockout

In the same year, Luger's group published a parallel set of experiments in Inflammatory Bowel Diseases. Kannengiesser and colleagues used DSS colitis and a second model, CD45RB-high T-cell transfer colitis, and tracked weight loss, colon histology and myeloperoxidase (MPO) activity as a marker of neutrophil infiltration (Kannengiesser et al., Inflammatory Bowel Diseases, 2008).

In DSS colitis, KPV-treated mice recovered earlier and regained significantly more body weight. Inflammatory infiltrates on histology were significantly reduced, as was MPO activity in colonic tissue. In the transfer model, treatment led to recovery, weight regain and reduced inflammatory change.

The most striking experiment used mice with a non-functional melanocortin-1 receptor. Those animals were given DSS and treated with KPV, and every animal in the treatment group survived a colitis that was otherwise fatal. The authors took this as evidence that KPV's effect is "at least partially independent" of MC1R signalling, which fits the PepT1 route proposed in Atlanta.

Two independent laboratories, two continents, four mouse models, one year. That is the foundation of the gut story, and it is still a mouse story.

Getting KPV to the colon: nanoparticles and hydrogels

Free KPV in drinking water is a blunt tool, because most of it is absorbed or degraded before reaching the colon. Merlin's group next loaded KPV into 400 nm polymer nanoparticles and wrapped them in an alginate-chitosan hydrogel designed to collapse in the colon.

In DSS mice, the encapsulated particles protected against inflammatory and histological damage, and the headline figure was efficiency: the nanoparticle route delivered a KPV concentration 12,000-fold lower than free KPV in solution with similar effect (Laroui et al., Gastroenterology, 2010).

In 2017 Bo Xiao and Merlin went further, coating KPV-loaded nanoparticles with hyaluronic acid so they would home to the colonic epithelial cells and macrophages involved in ulcerative colitis. The particles measured about 272 nm with a slightly negative surface charge, and when given orally in a chitosan-alginate hydrogel to colitis mice they reduced mucosal damage and TNF-alpha more than uncoated particles (Xiao et al., Molecular Therapy, 2017).

The approach is still being refined. A 2024 paper from Wenzhou Medical University built a temperature-sensitive hydrogel carrying KPV and epidermal growth factor that gelled within 10 seconds at body temperature, adhered to inflamed colon by electrostatic attraction and, given rectally to colitis rats, reduced weight loss, disease activity and colonic IL-1 beta, IL-6 and TNF-alpha (Li et al., ACS Applied Materials and Interfaces, 2024).

What has not been done: no human trials

The FDA reviewed KPV in 2026 for its compounding advisory committee. Its reviewers searched the medical literature and "did not identify data, such as clinical studies, on the use of KPV in humans". They also wrote that KPV does not appear to interact with the melanocortin receptors and that its molecular targets are unknown (FDA, Pharmacy Compounding Advisory Committee presentation, July 2026).

FDA staff recommended against adding KPV to the list of substances pharmacies may compound. On 23 July 2026 the advisory committee voted narrowly the other way, for KPV and several other peptides; the agency is not bound by the vote and had not finalised a decision as of this writing (BBC News, 23 July 2026).

In the UK, KPV is not a licensed medicine and is sold for laboratory research only. Researchers looking to buy kpv are buying a tripeptide with a solid mouse literature in colitis and no human efficacy or safety data.

How KPV is thought to act on NF-kappaB, and the skin and wound research that runs alongside the gut work, is covered in our post on KPV as an anti-inflammatory peptide.

LynxLab stocks kpv 10mg for research use at £28.99 a vial, tested to 99% purity with the batch certificate of analysis on the product page.

Frequently asked questions

What does KPV do in the gut?

In mouse colitis models, orally given KPV reduced inflammation, weight loss and pro-inflammatory cytokines (Dalmasso et al., 2008; Kannengiesser et al., 2008). It enters intestinal epithelial and immune cells through the PepT1 transporter, which appears in the colon during inflammatory bowel disease.

Has KPV been tested in people with IBD?

No. The FDA's 2026 review found no clinical studies of KPV in humans by any route. All the colitis evidence comes from mice and rats and from human cell lines.

Why is PepT1 important for KPV research?

PepT1 moves di- and tripeptides into cells. Merlin's group showed in 2001 that it is absent from healthy colon but present in ulcerative colitis and Crohn's disease, and in 2008 that KPV uses it to enter cells.

Where can I find KPV in the UK for research?

Laboratories can source kpv for research from UK suppliers in freeze-dried vials. It is not a licensed medicine anywhere, and no regulator has approved it for any use.

Sources

Research use only

KPV from LynxLab

10mg vials from £28.99. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy KPV